Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant small » significant male (Expand Search), significant all (Expand Search), significant shape (Expand Search)
significant anti » significant factor (Expand Search), significant health (Expand Search), significant change (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant small » significant male (Expand Search), significant all (Expand Search), significant shape (Expand Search)
significant anti » significant factor (Expand Search), significant health (Expand Search), significant change (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Cox proportional hazard ratios.
Published 2025“…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
-
10
Bioluminescent Doubling Time.
Published 2025“…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
-
11
Study Design.
Published 2025“…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
Presentation 1_Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients.pptx
Published 2024“…<p>Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. …”
-
20
Table 1_Repurposing of the small-molecule adrenoreceptor-inhibitor carvedilol for treatment of the fibrotic lung.xlsx
Published 2025“…</p>Methods<p>In silico modeling of dysregulated pathways in IPF and screening for putative interfering small molecules identified carvedilol as a promising anti-fibrotic agent. …”